Table of contents
July 2013 - Volume 89 - Suppl 1
STI & AIDS World Congress 2013 July 14-17 Vienna, Austria
- KL - Keynote lecture
- PL.01 - Plenary session 1
- PL.02 - Plenary session 2
- PL.03 - Plenary session 3: Anton Luger Memorial
- PL.04 - Plenary session 4
- PL.05 - Plenary session 5
- S.01 - Microbicides to prevent HIV/STD 2013: An Update
- S.02 - Translating and implementing the results of diagnostic assay evaluations: From the research laboratory to patient care
- S.03 - Advancing prevention of sexually transmitted infections through sexual health promotion: Opportunities and lessons learned (organised by CDC/WHO/ECDC)
- S.04 - Scaling up of HIV treatment programmes among the most at-risk populations in low- and middle-income countries
- S.05 - Fostering an Integrated Approach to the Control of Antimicrobial Resistance in Neisseria gonorrhoeae (WHO Symposium)
- S.06 - How does your partner know?
- S.07 - Bacterial virulence and host response
- S.08 - STI/HIV treatment guidelines: Important areas of clinical uncertainty
- S.09 - Molecular mechanisms of antimicrobial resistance
- S.10 - HIV treatment as prevention
- S.11 - National trends in sexual behaviour: USA, UK and Switzerland
- S.12 - STD vaccines and correlates of immunity
- S.13 - Challenges to a comprehensive approach to the prevention of HIV and STI among men who have sex with men in Europe (organised by ECDC)
- S.14 - New strategies and implementation of best practises for dual elimination of mother-to-child transmission of syphilis and HIV (organised by WHO)
- S.15 - Sexual networks and contagion (Insights from phylodynamic studies, behaviour diffusion, social media studies)
- S.16 - Challenging clinical conditions
- YI - American Sexually Transmitted Diseases Association – Young Investigators Symposium: research in progress: Highlights from the American STD association developmental awards programme
- O.01 - Microbial virulence and host response
- O.02 - Antimicrobial therapy for genital tract infections
- O.03 - Neisseria gonorrhoeae resistance: Superbug ante portas?
- O.04 - Vaginal infections and PID
- O.05 - Molecular analysis of STI pathogens and their environments
- O.06 - Clinical issues and potential solutions
- O.07 - Sexually transmitted infections: social and behavioural determinants and consequences
- O.08 - Get those partners treated!
- O.09 - Programme implementation and scaling up
- O.10 – HPV: genital tract malignancy and vaccination
- O.11 - HIV prevention and lessons learned from trials of HIV pre-exposure prophylaxis
- O.12 - Social determinants and structural interventions
- O.13 - Epidemic appraisal and strategic planning
- O.14 - Clinical syndromes
- O.15 - For lab rats and other mice and men
- O.16 - STI-Potpourri: Chlamydia, HPV and special populations
- O.17 - Programme evaluation
- O.18 - Diagnosis of sexually transmitted infections
- O.19 - Prevention and curing STIs: Who is the winner?
- O.20 - Sexual partnerships and networks
- O.21 - Antimicrobial resistance mechanisms in STI pathogens
- O.22 - Alternative screening tools and screening sites
- O.23 - Risk behaviours and preventive interventions
- P.01 - Basic Sciences Track
- P.02 - Clinical Sciences Track
- P.03 - Epidemiology and Prevention Sciences Track
- P.04 - Social and Behavioural Sciences Track
- P.05 - Translational and Implementation Sciences Track
- P.06 - Health Policy and Programme Sciences Track
